Biotech Archives - Page 747 of 795

2 minute read

Gilead Sciences Announces Trodelvy Significantly Improves Overall Survival In Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients In The TROPiCS-02 Study

August 15, 8:42 AM

Gilead Sciences, Inc. (NASDAQ:GILD) today announced statistically significant and clinically meaningful results from the second interim analysis of the key secondary endpoint of overall survival (OS) in the Phase 3

GILD

1 minute read

Virios Therapeutics Commences Mid-Stage Long-COVID Study

By Ragothaman Srinivasan

August 15, 8:27 AM

Virios Therapeutics (Nasdaq: VIRI) has initiated patient dosing in its exploratory Long-COVID trial evaluating IMC-2 (valacyclovir + celecoxib).

VIRI

2 minute read

Amarin Corporation Announces Research Evaluating VASCEPA/VAZKEPA And Subgroups From The REDUCE-IT Landmark Outcomes Trial To Be Presented At The European Society Of Cardiology Congress

By Benzinga Newsdesk

August 15, 8:02 AM

Amarin Corporation plc (NASDAQ:AMRN) today announced new supported and/or funded research on the effects of VASCEPA®/VAZKEPA (icosapent ethyl) in specific patient subgroups at increased risk of a cardiovascular (CV)

AMRN

2 minute read

BD, Accelerate Diagnostics Announce Global Commercial Collaboration

By Benzinga Newsdesk

August 15, 6:52 AM

BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, and Accelerate Diagnostics, Inc. (NASDAQ:AXDX) an innovator of rapid in-vitro diagnostics in microbiology, today announced a

AXDX

1 minute read

Raymond James Is Bearish On This Inflammatory Bowel Disease Player On Upcoming ‘Pipeline Reset’

By Vandana Singh

August 12, 6:37 PM

Raymond James downgraded Landos Biopharma Inc (NASDAQ:LABP) to Market Perform from Outperform following 2Q22 earnings and the first look at NX-13…

LABP

2 minute read

Recap Of Friday’s Biotech Catalysts – End Of the Day Summary

By Ragothaman Srinivasan

August 12, 5:13 PM

Pfizer (NYSE:PFE) announced positive top-line results from its pivotal U.S. Phase 3 study in infants evaluating its 20-valent…

ACER

1 minute read

Senate Finance Committee Expands Amgen’s Tax Probe: Report

By Vandana Singh

August 12, 2:04 PM

Senator Ron Wyden sent a letter to Amgen Inc (NASDAQ: AMGN) asking what methods the company has used to pay an average effective tax rate of around 12% over the past four years.

AMGN

1 minute read

Relief And Acer Therapeutics Secures Orphan Drug Designation From European Union For Metabolic Disorder Candidate

By Ragothaman Srinivasan

August 12, 11:40 AM

The European Commission has granted orphan medicinal product designation in the EU to Relief Therapeutics and Acer Therapeutics’ (NASDAQ: ACER) lead asset ACER-001 (sodium phenylbutyrate) for the potential treatment of patients with Maple Syrup Urine Disease (MSUD).

ACER